Envoy Medical, Inc. (NASDAQ:COCH - Get Free Report) CEO Brent Lucas purchased 62,500 shares of Envoy Medical stock in a transaction dated Thursday, February 12th. The stock was acquired at an average price of $0.40 per share, with a total value of $25,000.00. Following the acquisition, the chief executive officer owned 297,090 shares in the company, valued at approximately $118,836. This represents a 26.64% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Envoy Medical Stock Performance
Shares of COCH opened at $0.69 on Wednesday. The company has a 50 day moving average price of $0.67 and a 200-day moving average price of $0.89. Envoy Medical, Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $1.91. The stock has a market capitalization of $19.83 million, a PE ratio of -0.49 and a beta of 2.10.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on COCH. Wall Street Zen upgraded Envoy Medical to a "sell" rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Envoy Medical in a research report on Tuesday, January 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $9.50.
Check Out Our Latest Report on COCH
Hedge Funds Weigh In On Envoy Medical
Several institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Bancorp USA Inc. acquired a new stake in Envoy Medical during the third quarter worth about $60,000. Geode Capital Management LLC boosted its position in Envoy Medical by 111.3% in the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company's stock worth $65,000 after purchasing an additional 51,813 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in Envoy Medical in the 1st quarter worth approximately $276,000. Institutional investors and hedge funds own 8.59% of the company's stock.
About Envoy Medical
(
Get Free Report)
Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company's lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.
Envoy Medical's flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
